Below is a detailed analysis of the quarterly data for Fermenta Biotech Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
For Sales, as of Mar 2025, the value is 140.00 Cr.. The value appears to be declining and may need further review. It has decreased from 156.00 Cr. (Dec 2024) to 140.00 Cr., marking a decrease of 16.00 Cr..
For Expenses, as of Mar 2025, the value is 103.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 103.00 Cr..
For Operating Profit, as of Mar 2025, the value is 37.00 Cr.. The value appears to be declining and may need further review. It has decreased from 53.00 Cr. (Dec 2024) to 37.00 Cr., marking a decrease of 16.00 Cr..
For OPM %, as of Mar 2025, the value is 26.00%. The value appears to be declining and may need further review. It has decreased from 34.00% (Dec 2024) to 26.00%, marking a decrease of 8.00%.
For Other Income, as of Mar 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Dec 2024) to 4.00 Cr., marking an increase of 2.00 Cr..
For Interest, as of Mar 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.00 Cr. (Dec 2024) to 3.00 Cr., marking a decrease of 1.00 Cr..
For Depreciation, as of Mar 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 6.00 Cr..
For Profit before tax, as of Mar 2025, the value is 32.00 Cr.. The value appears to be declining and may need further review. It has decreased from 45.00 Cr. (Dec 2024) to 32.00 Cr., marking a decrease of 13.00 Cr..
For Tax %, as of Mar 2025, the value is -4.00%. The value appears to be improving (decreasing) as expected. It has decreased from 16.00% (Dec 2024) to -4.00%, marking a decrease of 20.00%.
For Net Profit, as of Mar 2025, the value is 33.00 Cr.. The value appears to be declining and may need further review. It has decreased from 38.00 Cr. (Dec 2024) to 33.00 Cr., marking a decrease of 5.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 11.68. The value appears to be declining and may need further review. It has decreased from 12.54 (Dec 2024) to 11.68, marking a decrease of 0.86.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
×
Quarterly Chart
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 1:29 pm
Metric
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Sales
139
142
155
164
302
403
292
376
397
349
335
469
Expenses
113
126
134
152
209
248
225
293
335
330
307
360
Operating Profit
26
16
21
12
93
156
66
83
62
18
28
110
OPM %
19%
11%
13%
7%
31%
39%
23%
22%
16%
5%
8%
23%
Other Income
3
0
1
3
9
6
12
8
8
-20
4
12
Interest
5
4
6
10
14
21
20
19
18
21
17
14
Depreciation
10
9
8
10
12
12
15
20
26
28
25
24
Profit before tax
14
3
7
-6
76
129
43
52
27
-51
-10
83
Tax %
24%
67%
61%
49%
28%
8%
-37%
18%
44%
4%
143%
8%
Net Profit
10
1
2
-9
46
117
60
43
15
-53
-24
76
EPS in Rs
2.86
0.17
-0.41
-4.14
12.21
42.71
20.23
15.46
5.25
-17.36
-7.84
26.12
Dividend Payout %
29%
249%
-51%
-5%
2%
1%
24%
16%
23%
-7%
-16%
0%
×
Profit & Loss Yearly Chart
YoY Net Profit Growth
Year
2014-2015
2015-2016
2016-2017
2017-2018
2018-2019
2019-2020
2020-2021
2021-2022
2022-2023
2023-2024
2024-2025
YoY Net Profit Growth (%)
-90.00%
100.00%
-550.00%
611.11%
154.35%
-48.72%
-28.33%
-65.12%
-453.33%
54.72%
416.67%
Change in YoY Net Profit Growth (%)
0.00%
190.00%
-650.00%
1161.11%
-456.76%
-203.07%
20.38%
-36.78%
-388.22%
508.05%
361.95%
Fermenta Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
Compounded Sales Growth
10 Years:
13%
5 Years:
10%
3 Years:
6%
TTM:
40%
Compounded Profit Growth
10 Years:
66%
5 Years:
6%
3 Years:
72%
TTM:
552%
Stock Price CAGR
10 Years:
21%
5 Years:
1%
3 Years:
18%
1 Year:
88%
Return on Equity
10 Years:
12%
5 Years:
6%
3 Years:
4%
Last Year:
23%
Last Updated: Unknown
No data available for the Balance Sheet data table.
Reserves and Borrowings Chart
Cash Flow
Month
Month
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Cash from Operating Activity +
14
15
4
2
59
90
34
63
43
116
105
41
Cash from Investing Activity +
-25
-18
-13
7
-101
-97
-44
-41
-26
-55
-16
-0
Cash from Financing Activity +
13
1
10
-12
89
12
-47
-1
-22
-41
-91
-51
Net Cash Flow
2
-2
1
-4
47
6
-57
21
-4
19
-1
-10
Free Cash Flow Chart
Financial Efficiency Indicators
Month
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Debtor Days
79
106
91
101
99
83
59
87
66
80
44
76
Inventory Days
225
149
125
160
208
234
347
594
441
380
309
245
Days Payable
134
120
95
113
147
183
169
260
169
154
109
182
Cash Conversion Cycle
171
136
122
148
160
134
237
421
338
306
244
139
Working Capital Days
72
73
4
20
115
90
97
202
171
180
123
108
ROCE %
8%
9%
3%
6%
2%
31%
41%
12%
13%
7%
-0%
3%
Financial Efficiency Indicators Chart
Share Holding Pattern
Month
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Promoters
59.58%
59.58%
59.58%
59.58%
59.58%
59.58%
62.06%
62.06%
62.06%
62.06%
62.06%
62.06%
FIIs
0.01%
0.01%
0.01%
0.01%
0.01%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.05%
DIIs
0.05%
0.05%
0.05%
0.05%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
38.37%
38.37%
38.37%
38.38%
38.45%
38.46%
36.00%
36.04%
36.05%
36.05%
36.11%
36.41%
Others
1.98%
1.98%
1.98%
1.98%
1.95%
1.95%
1.92%
1.89%
1.89%
1.89%
1.82%
1.47%
No. of Shareholders
18,578
17,518
17,472
17,971
17,610
16,897
16,148
15,721
15,150
15,178
14,589
13,221
Shareholding Pattern Chart
No. of Shareholders
This stock is not held by any mutual fund.
ROCE Trend
EPS Trend
Key Financial Ratios
Month
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
FaceValue
5.00
5.00
5.00
5.00
5.00
Basic EPS (Rs.)
26.35
-7.99
-17.85
5.33
15.77
Diluted EPS (Rs.)
26.35
-7.99
-17.85
5.33
15.69
Cash EPS (Rs.)
34.50
0.24
-8.77
14.08
21.78
Book Value[Excl.RevalReserv]/Share (Rs.)
122.91
98.76
108.08
128.76
124.90
Book Value[Incl.RevalReserv]/Share (Rs.)
122.91
98.76
108.08
128.76
124.90
Revenue From Operations / Share (Rs.)
160.95
116.25
121.27
138.15
130.79
PBDIT / Share (Rs.)
41.69
13.62
8.88
24.12
31.17
PBIT / Share (Rs.)
33.39
5.06
-0.90
15.26
24.13
PBT / Share (Rs.)
28.53
-3.42
-17.98
9.34
17.90
Net Profit / Share (Rs.)
26.19
-8.31
-18.56
5.22
14.74
NP After MI And SOA / Share (Rs.)
26.35
-7.99
-17.85
5.35
15.77
PBDIT Margin (%)
25.90
11.71
7.32
17.46
23.83
PBIT Margin (%)
20.74
4.34
-0.74
11.04
18.44
PBT Margin (%)
17.72
-2.94
-14.82
6.76
13.68
Net Profit Margin (%)
16.27
-7.15
-15.30
3.77
11.27
NP After MI And SOA Margin (%)
16.37
-6.86
-14.71
3.87
12.06
Return on Networth / Equity (%)
21.43
-7.98
-16.36
4.15
12.62
Return on Capital Employeed (%)
24.19
3.89
-0.61
8.81
14.56
Return On Assets (%)
12.50
-4.20
-8.09
2.18
6.62
Long Term Debt / Equity (X)
0.04
0.14
0.26
0.30
0.30
Total Debt / Equity (X)
0.30
0.45
0.68
0.63
0.57
Asset Turnover Ratio (%)
0.80
0.56
0.52
0.55
0.57
Current Ratio (X)
1.58
1.40
1.21
1.52
1.48
Quick Ratio (X)
0.99
0.89
0.58
0.74
0.70
Inventory Turnover Ratio (X)
1.13
0.70
0.77
0.91
1.06
Dividend Payout Ratio (NP) (%)
0.00
-15.65
-7.00
46.68
0.00
Dividend Payout Ratio (CP) (%)
0.00
217.49
-15.50
17.58
0.00
Earning Retention Ratio (%)
0.00
115.65
107.00
53.32
0.00
Cash Earning Retention Ratio (%)
0.00
-117.49
115.50
82.42
0.00
Interest Coverage Ratio (X)
8.57
2.31
1.23
4.07
5.00
Interest Coverage Ratio (Post Tax) (X)
6.38
0.02
-0.20
1.88
3.37
Enterprise Value (Cr.)
835.62
505.89
464.45
795.24
883.96
EV / Net Operating Revenue (X)
1.78
1.51
1.33
2.00
2.34
EV / EBITDA (X)
6.87
12.87
18.12
11.43
9.83
MarketCap / Net Operating Revenue (X)
1.70
1.30
0.88
1.49
1.91
Retention Ratios (%)
0.00
115.65
107.00
53.31
0.00
Price / BV (X)
2.23
1.51
0.98
1.59
2.00
Price / Net Operating Revenue (X)
1.70
1.30
0.88
1.49
1.91
EarningsYield
0.09
-0.05
-0.16
0.02
0.06
After reviewing the key financial ratios for Fermenta Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
For Basic EPS (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
For Diluted EPS (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
For Cash EPS (Rs.), as of Mar 25, the value is 34.50. This value is within the healthy range. It has increased from 0.24 (Mar 24) to 34.50, marking an increase of 34.26.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 122.91. It has increased from 98.76 (Mar 24) to 122.91, marking an increase of 24.15.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 122.91. It has increased from 98.76 (Mar 24) to 122.91, marking an increase of 24.15.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 160.95. It has increased from 116.25 (Mar 24) to 160.95, marking an increase of 44.70.
For PBDIT / Share (Rs.), as of Mar 25, the value is 41.69. This value is within the healthy range. It has increased from 13.62 (Mar 24) to 41.69, marking an increase of 28.07.
For PBIT / Share (Rs.), as of Mar 25, the value is 33.39. This value is within the healthy range. It has increased from 5.06 (Mar 24) to 33.39, marking an increase of 28.33.
For PBT / Share (Rs.), as of Mar 25, the value is 28.53. This value is within the healthy range. It has increased from -3.42 (Mar 24) to 28.53, marking an increase of 31.95.
For Net Profit / Share (Rs.), as of Mar 25, the value is 26.19. This value is within the healthy range. It has increased from -8.31 (Mar 24) to 26.19, marking an increase of 34.50.
For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
For PBDIT Margin (%), as of Mar 25, the value is 25.90. This value is within the healthy range. It has increased from 11.71 (Mar 24) to 25.90, marking an increase of 14.19.
For PBIT Margin (%), as of Mar 25, the value is 20.74. This value exceeds the healthy maximum of 20. It has increased from 4.34 (Mar 24) to 20.74, marking an increase of 16.40.
For PBT Margin (%), as of Mar 25, the value is 17.72. This value is within the healthy range. It has increased from -2.94 (Mar 24) to 17.72, marking an increase of 20.66.
For Net Profit Margin (%), as of Mar 25, the value is 16.27. This value exceeds the healthy maximum of 10. It has increased from -7.15 (Mar 24) to 16.27, marking an increase of 23.42.
For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.37. This value is within the healthy range. It has increased from -6.86 (Mar 24) to 16.37, marking an increase of 23.23.
For Return on Networth / Equity (%), as of Mar 25, the value is 21.43. This value is within the healthy range. It has increased from -7.98 (Mar 24) to 21.43, marking an increase of 29.41.
For Return on Capital Employeed (%), as of Mar 25, the value is 24.19. This value is within the healthy range. It has increased from 3.89 (Mar 24) to 24.19, marking an increase of 20.30.
For Return On Assets (%), as of Mar 25, the value is 12.50. This value is within the healthy range. It has increased from -4.20 (Mar 24) to 12.50, marking an increase of 16.70.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.14 (Mar 24) to 0.04, marking a decrease of 0.10.
For Total Debt / Equity (X), as of Mar 25, the value is 0.30. This value is within the healthy range. It has decreased from 0.45 (Mar 24) to 0.30, marking a decrease of 0.15.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.80. It has increased from 0.56 (Mar 24) to 0.80, marking an increase of 0.24.
For Current Ratio (X), as of Mar 25, the value is 1.58. This value is within the healthy range. It has increased from 1.40 (Mar 24) to 1.58, marking an increase of 0.18.
For Quick Ratio (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has increased from 0.89 (Mar 24) to 0.99, marking an increase of 0.10.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.13. This value is below the healthy minimum of 4. It has increased from 0.70 (Mar 24) to 1.13, marking an increase of 0.43.
For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has increased from -15.65 (Mar 24) to 0.00, marking an increase of 15.65.
For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 217.49 (Mar 24) to 0.00, marking a decrease of 217.49.
For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 115.65 (Mar 24) to 0.00, marking a decrease of 115.65.
For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has increased from -117.49 (Mar 24) to 0.00, marking an increase of 117.49.
For Interest Coverage Ratio (X), as of Mar 25, the value is 8.57. This value is within the healthy range. It has increased from 2.31 (Mar 24) to 8.57, marking an increase of 6.26.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.38. This value is within the healthy range. It has increased from 0.02 (Mar 24) to 6.38, marking an increase of 6.36.
For Enterprise Value (Cr.), as of Mar 25, the value is 835.62. It has increased from 505.89 (Mar 24) to 835.62, marking an increase of 329.73.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.78. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 1.78, marking an increase of 0.27.
For EV / EBITDA (X), as of Mar 25, the value is 6.87. This value is within the healthy range. It has decreased from 12.87 (Mar 24) to 6.87, marking a decrease of 6.00.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.70, marking an increase of 0.40.
For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 115.65 (Mar 24) to 0.00, marking a decrease of 115.65.
For Price / BV (X), as of Mar 25, the value is 2.23. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 2.23, marking an increase of 0.72.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.70, marking an increase of 0.40.
For EarningsYield, as of Mar 25, the value is 0.09. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.09, marking an increase of 0.14.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
×
Profitability Ratios (%)
Liquidity Ratios
Liquidity Ratios (%)
Interest Coverage Ratios (%)
Valuation Ratios
Fair Value
Fair Value of Fermenta Biotech Ltd as of June 26, 2025 is: 272.82
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.
As of June 26, 2025, Fermenta Biotech Ltd is Overvalued by 10.55% compared to the current share price 305.00
Intrinsic Value of Fermenta Biotech Ltd as of June 26, 2025 is: 302.99
Calculation basis:
Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.
This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.
As of June 26, 2025, Fermenta Biotech Ltd is Overvalued by 0.66% compared to the current share price 305.00
Last 5 Year EPS CAGR: 11.06%
*Investments are subject to market risks
Strength and Weakness
Unable to fetch valid data for stock valuation.
Stock Analysis
Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fermenta Biotech Ltd:
Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
ROE%: 21.43% (Industry Average ROE: 15.19%)
ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
Stock P/E: 11.8 (Industry average Stock P/E: 103.22)
Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
Total Debt / Equity: 0.3
Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions. Stock Rating:
About the Company - Qualitative Analysis
Fermenta Biotech Ltd. is a Public Limited Listed company incorporated on 01/05/1951 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L99999MH1951PLC008485 and registration number is 008485. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 430.53 Cr. and Equity Capital is Rs. 14.58 Cr. for the Year ended 31/03/2025.
FAQ: Stock data is invalid or not in the correct format.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Fermenta Biotech Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
